The pTau217 blood test is rapidly transforming Alzheimer’s care.
It makes early detection possible, so that treatment can be started early, even before symptoms become noticeable.
Louis shares a Science Perspective on pTau217, a blood biomarker that detects early Alzheimer's pathology non-invasively, potentially years before symptoms.
The pTau217 blood test is rapidly transforming Alzheimer’s care.
It makes early detection possible, so that treatment can be started early, even before symptoms become noticeable.
In a new Science Perspective, researchers highlight a newly developed blood-based biomarker, pTau217, which allows detection of early pathological changes associated with Alzheimer’s disease without invasive procedures.
Learn more:
Paper · Science · 2026Tracking the turning point in Alzheimer’s diseaseA blood biomarker reveals the mechanistic shift from amyloid to tau pathologyscience.org